Trial Profile
An Observer-Blinded, Placebo-Controlled, Multiple-Ascending, Dose-Escalation Study to Explore the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeat Intravenous Administrations of UTTR1147A in Healthy Volunteers and Patients With Ulcerative Colitis and Crohn's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Efmarodocokin alfa (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Genentech
- 02 Feb 2023 Results published in the Gut
- 06 Mar 2020 Status changed from active, no longer recruiting to completed.
- 04 Feb 2020 Planned End Date changed from 7 Feb 2020 to 21 Feb 2020.